GeoVax Expands Scientific Advisory Board with Global Vaccine and Immunology Experts
TL;DR
GeoVax strengthens its competitive edge by adding top vaccine and immunology experts to its advisory board, accelerating development of vaccines for underserved populations and cancers.
GeoVax expanded its Scientific Advisory Board with experts in vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised medicine to guide its MVA platform and clinical strategy.
GeoVax's enhanced advisory board focuses on developing vaccines that protect vulnerable populations in low-income countries and immunocompromised patients, aiming for more equitable global health outcomes.
GeoVax assembled a dream team of vaccine experts including Oxford's Teresa Lambe and T-cell mapping pioneer Alessandro Sette to tackle infectious diseases and cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancers, announced an update to its Scientific Advisory Board with the addition of four internationally recognized experts. This strategic expansion supports the company's development efforts with its MVA and multi-antigen MVA vector platform for vaccines targeting biothreat pathogens and vulnerable populations.
The newly appointed members join previously announced SAB member Prof. Teresa Lambe, PhD, OBE, FMedSci, Calleva Head of Vaccine Immunology at Oxford Vaccine Group and Jenner Institute, University of Oxford. The new appointments include Dr. Alessandro Sette, Director of Biological Sciences at the Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, an authority in T-cell epitope mapping and immune correlates of protection who leads the NIH Immune Epitope Database (IEDB).
Prof. Lance Turtle, PhD, MBBS, FRCP, DTMH, Chair in Immunity and Infectious Diseases at University of Liverpool and Royal Liverpool Hospital, brings expertise in viral pathogenesis and post-infection immune recovery. Prof. Thushan I. de Silva, MBBS, PhD, MRCP, Professor of Infectious Diseases and Immunology at University of Sheffield, contributes knowledge in human viral immunology, vaccine responses, and global immunosurveillance. Dr. Joshua A. Hill, MD, FIDSA, Associate Professor at University of Washington School of Medicine and Fred Hutchinson Cancer Center, specializes in vaccine response in immunocompromised and transplant patients.
David Dodd, GeoVax Chairman and CEO, stated that assembling this exceptional team strengthens GeoVax's position at the forefront of vaccine innovation. Their combined experience aligns with the company's mission to deliver durable, broad-spectrum protection to both global and immunocompromised populations. Dr. Kelly McKee, Chief Medical Officer, noted that the addition ensures clinical strategy is guided by cutting-edge immunology insight and global research expertise, particularly for protecting vulnerable populations in low and middle income countries and immunocompromised patients underserved by traditional approaches.
Dr. Mark Newman, Chief Scientific Officer, emphasized that the expanded SAB strengthens multiple aspects of the company's R&D platform, ensuring vaccine and immunotherapy candidates deliver real-world impact. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients, a booster vaccine in patients with chronic lymphocytic leukemia, and a more robust COVID-19 booster among healthy patients who previously received mRNA vaccines.
GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation. The company maintains a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.
Curated from NewMediaWire
